Clinical Scorecard: Utilization of CorVad as a Temporary Support Prior to LVAD Placement in Advanced Heart Failure with Cardiogenic Shock: A Case Series of Three Patients
At a Glance
Category
Detail
Condition
Cardiogenic Shock (CS)
Key Mechanisms
CorVad provides hemodynamic support by aspirating blood from the left ventricle into the ascending aorta, achieving left ventricular unloading and improving systemic perfusion.
Target Population
Patients with end-stage heart failure and SCAI stage D cardiogenic shock.
Care Setting
First Affiliated Hospital of Anhui Medical University
Key Highlights
CorVad support led to rapid improvements in hemodynamic parameters.
All patients successfully underwent elective LVAD implantation without complications.
Mild hemolysis indicators were observed post-implantation, without severe complications.
Patients remained alive and ambulatory at 30-day and 3-month follow-up.
Guideline-Based Recommendations
Diagnosis
Persistent hypotension (systolic blood pressure < 90 mmHg or dependence on vasoactive agents after adequate volume resuscitation).
Cardiac index < 2.2 L min⁻¹ m⁻², and evidence of tissue hypoperfusion.
Management
CorVad implantation for hemodynamic stabilization prior to LVAD.
Monitoring & Follow-up
Serial monitoring of hemoglobin, hematocrit, and indirect bilirubin levels postoperatively.
Risks
Potential for mild hemolysis or transient hemodilution.
Patient & Prescribing Data
Three patients with end-stage heart failure and cardiogenic shock.
CorVad serves as a bridge to LVAD, allowing for hemodynamic stabilization.
Clinical Best Practices
Ensure hemodynamic stability before transitioning to LVAD.
Monitor lactate levels and end-organ function during support.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
